Gene therapy for spinal muscular atrophy

What the study found

In a 2017 New England Journal of Medicine trial, infants with spinal muscular atrophy type 1 — a severe inherited motor-neuron disease caused by a missing or faulty SMN1 gene — received a one-time intravenous infusion of onasemnogene abeparvovec, which uses an AAV9 viral vector to deliver a working copy of the SMN1 gene. Treated infants survived longer without permanent ventilation and reached motor milestones, such as sitting unassisted, that untreated infants with this type almost never achieve.

Why it matters

SMA type 1 is usually fatal or severely disabling in early childhood. Replacing the missing gene at the source, rather than only managing symptoms, was a landmark for inherited-disease gene therapy and supported the therapy's later regulatory approval. It also reframed a fatal diagnosis as potentially treatable if caught early.

Analysis — the pattern

This fits a broader pattern (analysis): AAV-delivered gene replacement is being pursued across many single-gene diseases, and outcomes appear best when treatment comes early, before irreversible motor-neuron loss. That timing logic is one reason newborn screening for SMA has expanded. Whether a single dose lasts a lifetime, and how the immune system reacts to the viral vector, are open questions the field is still answering.

What is still uncertain

Early trials were small and enrolled specific patients. Long-term durability, the possibility that effects wane and re-dosing is needed, immune reactions to the vector, and very high cost remain active concerns, and results depend heavily on how early treatment is given.